Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transition From Parenteral Prostanoids to Inhaled Treprostinil
NCT01268553Phase 4Completed
- Sponsor
- The Lundquist Institute
- Start
- Aug 2010
- Primary completion
- Oct 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by The Lundquist Institute. Primary endpoint: Number of Participants Without Adverse Events at 12 weeks. Started Aug 2010; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01268553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01268553.